Serum Prostate-Specific Antigen in a Community-Based Population of Healthy Men: Establishment of Age-Specific Reference Ranges

JAMA: The Journal of the American Medical Association

Volumn 270, Issue 7, 1993, Pages 860-864

  Oesterling, Joseph E ^a   Jacobsen, Steven J ^a   Chute, Christopher G ^a   Guess, Harry A ^a   Girman, Cynthia J ^a   Panser, Laurei A ^a   Lieber, Michael M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGING; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER THERAPY; COMMUNITY CARE; EARLY DIAGNOSIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; STATISTICAL ANALYSIS;

ADULT; AGE FACTORS; AGED; COHORT STUDIES; HUMAN; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR MARKERS, BIOLOGICAL;

EID: 0027244140     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1993.03510070082041     Document Type: Article

References (29)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin. 1993;43:7-26.
2. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42-46.
3. American Urological Association. Early detection of prostate cancer and use of transrectal ultrasound. In: American Urological Association 1992 Policy Statement Book. Baltimore, Md: American Urological Association; 1992:4.20.
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
5. Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145: 907-923.
6. Brawer MK. Prostatic intraepithelial neoplasia and prostate-specific antigen. Urology. 1989; 34(suppl):62-65.
7. Robles JM, Morell AR, Redorta JP, de Torres Mateos JA, Rosello AS. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study. Eur Urol. 1988;14:360-366.
8. Glenski WJ, Malek RS, Myrtle JF, Oesterling JE. Sustained, substantially increased concentration of prostate-specific antigen in the absence of prostatic malignant disease: an unusual clinical scenario. Mayo Clin Proc. 1992;67:249-252.
9. Oesterling JE. Prostate-specific antigen: improving its ability to diagnose early prostate cancer. JAMA. 1992;267:2236-2238.
10. Benson MC, Whang IS, Pontuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815-816.
11. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147:817-821.
12. Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW, Walsh PC. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol. 1989;141:987-992.
13. Kleer E, King BF, Oesterling JE, Weaver AL, Lewis RW. Estimation of prostatic volume: comparison of transrectal ultrasonography and magnetic resonance imaging using various formulas with pathologic correlation. Am J Radiol. In press.
14. Collins GN, Raab GM, Hehir M, King BF, Garraway WM. Observer variability and reproducibility of transrectal ultrasound in the measurement of prostatic volume. Br J Radiol. In press.
15. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85-89.
16. Panser LA, Chute CG, Girman CJ, et al. Effect of several recruitment strategies on response rates at baseline in a prospective cohort investigation: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Am J Epidemiol. In press.
17. Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988; 139:766-772.
18. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol. 1991; 145:984-987.
19. Elveback LR, Guillier CL, Keating FR Jr. Health, normality, and the ghost of Gauss. JAMA. 1970;211:69-75.
20. Cooner WH. Early diagnosis of prostate cancer. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr. Campbell's Urology. 6th ed, update 4. Philadelphia, Pa: WB Saunders Co; 1993:1-10.
21. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-2220.
22. Klee GG, Dodge L, Zincke H, Oesterling JE. Measurement of serum prostate-specific antigen concentration using the IMx PSA assay. J Urol. In press.
23. Vesselia RL, Noteboom J, Lange PH. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Clin Chem. 1992;38:2044-2054.
24. Chan DW, Bruzek DJ, Oesterling JE, Rock RC, Walsh PC. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem. 1987;33:1916-1920.
25. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE, for the Prostate Patient Outcomes Research Team. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA. 1993;269:2633-2636.
26. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993;269:2650-2658.
27. Whitmore WF Jr. Management of clinically localized prostatic cancer: an unresolved problem. JAMA. 1993;269:2676-2677.
28. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479.
29. Oesterling JE, Bilhartz DL, Tindall DJ. Clinically useful serum markers for adenocarcinoma of the prostate, II: prostate-specific antigen. Am Urol Assoc Update Ser. 1991;10:137-144.